I suspect they are progressively reducing Symbio debt? Ultimately their goal would be to be as debt free as is possible, ie: have creditors reasonably up to date and perhaps even paid before due.
Given their published margins and the fact that expenses have not increased yet cash and revenue are up, it is a fair assumption that they are paying more to Symbio in the quarter than what was actually incurred in the quarter.
Assumptions of course but a reasonable guess. Remember that 2 of the 4 MNF directors own Synbio so they would hardly be avoiding the outstanding debts they owe to themselves now would they, lol.
MNF Price at posting:
8.9¢ Sentiment: Buy Disclosure: Held